Doxorubicin–PAMAM dendrimer complex attached to liposomes: Cytotoxic studies against human cancer cell lines

Papagiannaros, Aristarchos; Dimas, Kostas; Papaioannou, George Th.; Demetzos, Costas

doi:10.1016/j.ijpharm.2005.05.039

Cited by 111 publications

(68 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Liposomes composed of HePC:eggphosphatidylcholine: stearylamine (HePC:EPC:SA) 10:10:0.1 (molar ratio), and eggphosphatidylcholine:stearylamin (EPC:SA) 10:0.1 (molar ratio) incorporated the doxorubicin-PAMAM (3:1 molar ratio) complex. The complex incorporated into liposome (HePC:EPC:SA) 10:10:0.1 (molar ratio), showed a delayed release of doxorubicin that is crucial for reducing its adverse effects and increasing its therapeutic index (Papagiannaros et al, 2005). These findings were very close to those published for the acidic drug methotrexete (Khopade et al, 2002), where claimed that the release was lowered from a dendrimeric liposomal formulation.…”

Section: Final Characterization F(chi-) or (Hy-)-amcddnsssupporting

confidence: 80%

“…A modulatory liposomal controlled release system (MLCRS) combined liposomal and dendrimeric technologies incorporating the anticancer drug doxorubicin has been recently reported (Papagiannaros et al, 2005) while dendrimers locked-into liposomal formulation (D locked-in L) is a new term in the drug delivery (Tekade et al, 2009;Gardikis et al, 2010a) and considered as a class of MLCRSs. We followed the concept of using acronyms, in order to reach to a specific description of modulatory controlled release nanosystems (MCRnSs).…”

Section: Advanced Drug Delivery Nanosystems and A Proposal To Their Cmentioning

confidence: 99%

See 1 more Smart Citation

Advanced drug delivery nanosystems (aDDnSs): a mini-review

Demetzos¹,

Pippa²

2013

Drug Delivery

Self Cite

View full text Add to dashboard Cite

Significant progress has been made in nanoscale drugs and delivery systems employing diverse chemical formulations to facilitate the rate of drug delivery and to improve its pharmacokinetics. Biocompatible nanomaterials have been used as biological markers, contrast agents for imaging, healthcare products, pharmaceuticals, drug-delivery systems as well as in detection, diagnosis and treatment of various types of diseases. The classification of drug delivery nanosystems (DDnSs) is a crucial issue and fundamental efforts on this subject are missing from the literature. This article deals with the classification of DDnSs with a modulatory controlled release profile (MCR) denoted as modulatory controlled release nanosystems (MCRnSs). Conventional (c) and advanced (a) DDnSs are denoted by the acronyms cDDnSs and aDDnSs, and can be composed of a single or more than one biomaterials, respectively. The classification was based on their characteristics such as: surface functionality (f), the nature of biomaterials used and the kind of interactions between biomaterials. The aDDnSs can be classified as hybridic (Hy-) or chimeric (Chi-) based on the nature -same or different respectively -of biomaterials and inorganic materials used. The nature of the elements used for producing advanced biomaterials is of great importance and medicinal chemistry contributes effectively to the production of aDDnSs.

show abstract

Section: Final Characterization F(chi-) or (Hy-)-amcddnsssupporting

confidence: 80%

Section: Advanced Drug Delivery Nanosystems and A Proposal To Their Cmentioning

confidence: 99%

Advanced drug delivery nanosystems (aDDnSs): a mini-review

Demetzos¹,

Pippa²

2013

Drug Delivery

Self Cite

View full text Add to dashboard Cite

show abstract

“…AZTdendrimer complex was prepared by reported stirring method [14]. Initially, drug-dendrimer complex was prepared with three molar ration of AZT:dendrimer 10:1, 5:1 and 3:1 and optimized with respect to entrapment efficiency and results of in vitro drug release study of complex.…”

Section: Resultsmentioning

confidence: 99%

“…AZT-dendrimer complex was prepared as per method reported by Papagiannaros et al [14]. AZT was dissolved in methanol and synthesized PETIM dendrimer was added.…”

Section: Development and In-vitro Characterization Of Aztdendrimer Comentioning

confidence: 99%

In-vitro and in-vivo Evaluation of Poly (Propyl Ether Imine) (PETIM) Dendrimer for Sustained Delivery of Zidovudine

Kumar¹

2013

J Antivir Antiretrovir

View full text Add to dashboard Cite

Study background: Acquired immunodeficiency syndrome (AIDS) is a severe disease of immune system caused by Human Immunodeficiency Virus (HIV). Zidovudine (AZT) is an effective antiretroviral drug against HIV. Due to its poor bioavailability (50-60%) and short elimination half life (0.5-3 h), frequent administration of zidovudine is required resulting into dose dependent hematological toxicity. In the present study, an attempt was made to develop sustained release formulation of AZT employing the poly (propyl ether imine) (PETIM) dendrimer as a carrier. Methods:The AZT-dendrimer complex was prepared and studied by Fourier transform infrared (FTIR) analysis and nuclear magnetic resonance (NMR) spectroscopy. The entrapment efficiency and in-vitro drug release studies were conducted by dialysis bag method. Hemolytic toxicity, pharmacokinetic and biodistribution studies were performed to evaluate the biosafety and sustained release characteristic of prepared formulation. Results and Conclusion:The cumulative amount of zidovudine released in 1 h from the AZT-dendrimer formulation was 6.5 ± 0.3 % compared with 95.8 ± 4.1% from the control drug solution. Zidovudine release was prolonged upto 14 h with zidovudine-dendrimer complex (94.3 ± 3.8%). The findings of present investigation illustrated that PETIM dendrimer effectively encapsulate AZT, and can be used as a biosafe carrier for sustained delivery of zidovudine.

show abstract

“…Similar concept was used to increase solubility and uptake flux of several anticancer drugs, like methoxyestradiol , adriamycin and methotrexate (Kojima et al, 2000), a plant alkaloid camptothecin (Cheng et al, 2008), doxorubicidin (Papagiannaros et al, 2005), and dimethoxycurcumin (Markatou et al 2007). Moreover, nifedipine -a calcium channel blocking agent (Devarakonda et al, 2004(Devarakonda et al, , 2005, a loop diuretic furosemide (Devarakonda et al, 2007, antipsychotic drug risperidone (Prieto et al, 2011), a hypolipidemic drug (Kulhari et al, 2011), antibiotic quinolones (Cheng et al, 2007), antibacterial sulfamethoxazole (Ma et al, 2007), as well as ophtalmic drugs pilocarpine nitrate and tropicamide (Vandamme & Brobeck, 2005) were also supported by PAMAM dendrimers as carrier.…”

mentioning

confidence: 99%